• Top 15 specialty pharmacies by 2023 revenue

    Two in five accredited specialty pharmacies are owned by hospitals and other healthcare providers, but the nation's three biggest pharmacy benefit managers accounted for 67% of specialty pharmacy revenue in 2023, according to Drug Channels. 
  • How does your system manage rare disease patients? Becker's wants to hear.

    Fill out this short survey here and attend our annual meeting for free.
  • Leqembi's rollout becomes a crawl

    About nine months after the FDA fully approved an Alzheimer's drug for the first time, the medicine is trudging through insurance barriers and hesitations from potential patients, the Chicago Tribune reported April 12. 
  • Pfizer to lay off 119, wind down plant's construction

    Pfizer plans to lay off 119 workers at a facility in Everett, Wash., which the drugmaker acquired in its Seagen deal. 
  • Congress probes popular China-based drugmaker

    WuXi AppTec, a drugmaker in China that manufactures multiple chemotherapies for U.S. patients, is facing scrutiny from lawmakers concerned about security threats, The New York Times reported April 15. 
  • The state of hospital pharmacies in 2024: 10 notes

    In 2024, healthcare pharmacy executives are focused on standardizing their formularies and streamlining drug purchasing, according to 275 hospital pharmacy leaders surveyed by Bluesight. 
  • California drugmaker weighs sale

    Janux Therapeutics, a biopharmaceutical company based in San Diego, is considering selling the business and other options, people with knowledge of the matter told Bloomberg. 
  • Drug shortages hit 23-year high: ASHP

    The number of ongoing drug shortages in the U.S. is at its highest since 2001 — when the American Society of Health-System Pharmacists began tracking data. There are now 323 medications in low supply. 
  • RSV vaccine is safe for young, middle-aged adults: Pfizer

    The U.S. might soon see an approved respiratory syncytial virus vaccine for adults younger than 60. 
  • The pros and cons of MA's biosimilar rule, per 1 pharmacist group

    Biosimilars can now be substituted as part of regular formulary maintenance changes, according to CMS' Medicare Advantage and Part D Final Rule for 2025. However, the change could significantly increase patient cost sharing, according to an article on the American Society of Health-System Pharmacists website.
  • Top PBMs by 2023 market share

    Three pharmacy benefit managers accounted for nearly 80% of all prescription claims handled in 2023, according to an April 9 report from the Drug Channels Institute.
  • How pharmacy miscommunication can result in patient death: Case study

    A jury awarded $42.4 million to the estate of a patient who died after staff failed to get the patient's baclofen prescription filled in a timely manner, a case study posted on the American Pharmacy Association website said.
  • 25 drugs at Mark Cuban's online pharmacy with biggest cost reductions

    Two years after launching, Mark Cuban Cost Plus Drugs now sells hundreds of generics and about 20 branded medications for a discounted rate. It also partners with hospitals, independent pharmacies and pharmacy benefit managers. 
  • Kaiser pharmacists secure mid-contract wage increases

    UFCW 3000, a union representing about 50,000 workers at health systems, retail stores and other businesses in three states, said it secured wage increases for some Kaiser Permanente employees. 
  • New York drugmaker files for bankruptcy

    Acorda Therapeutics filed for Chapter 11 bankruptcy April 1. 
  • Pharmacist pay by state

    The average pharmacist's salary in the U.S. is $134,790, and 15 states and Washington, D.C., are above the average, according to the most recent data from the Bureau of Labor Statistics. 
  • HHS 'misses the mark' in drug shortage proposal, ASHP says

    The American Society of Health-System Pharmacists partly welcomed HHS' 18-page policy recommendations for drug shortage strategies, but the organization said it "proposes concerning penalties."
  • Amylyx to swipe ALS from market after study failure

    Amylyx Pharmaceuticals is withdrawing its FDA-approved therapy for amyotrophic lateral sclerosis, Relyvrio, from the market after a phase 3 study failure, the company said April 4. 
  • CVS Caremark leader jabs Cost Plus Drugs; Mark Cuban responds

    David Joyner, executive vice president of CVS Health and president of CVS Caremark, called out Mark Cuban's drug company in a paid op-ed Fortune published April 3. 
  • 5 top-paying industries for pharmacists

    On average, general hospitals pay pharmacists more than retailers, but both industries are not among the five highest paying for the profession, according to data from the Bureau of Labor Statistics.
  • FDA approves antibiotic for 3 uses

    On April 3, the FDA approved Zevtera, an antibiotic with three different uses. 

Featured Whitepapers

Featured Webinars